Clinical Trial Update: A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ES102 in combination with toripalimab for advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ES102 (ES102)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING